Scarica l'app Stockscreener
6.05
3.60%
0.21
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARDX Giù?
Forum
Previsione
Precedente Chiudi:
$5.84
Aprire:
$5.9
Volume 24 ore:
9.84M
Relative Volume:
2.69
Capitalizzazione di mercato:
$1.49B
Reddito:
$427.68M
Utile/perdita netta:
$-58.06M
Rapporto P/E:
-25.40
EPS:
-0.2382
Flusso di cassa netto:
$-37.50M
1 W Prestazione:
+4.49%
1M Prestazione:
-0.98%
6M Prestazione:
+6.51%
1 anno Prestazione:
+67.59%
Intervallo 1D:
$5.7497
$6.07
Intervallo di 1 settimana:
$5.575
$6.07
Portata 52W:
$3.49
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Nome
Ardelyx Inc
Settore
Industria
Telefono
510-745-7047
Indirizzo
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
6.05 | 1.49B | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-09-03 | Ripresa | Raymond James | Strong Buy |
| 2025-06-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-02 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Ripresa | Ladenburg Thalmann | Buy |
| 2025-03-04 | Iniziato | BTIG Research | Buy |
| 2024-11-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-18 | Iniziato | Raymond James | Strong Buy |
| 2023-09-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-25 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-11-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Downgrade | Jefferies | Buy → Hold |
| 2021-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-23 | Iniziato | Wedbush | Outperform |
| 2021-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Ripresa | Citigroup | Buy |
| 2020-02-18 | Ripresa | Jefferies | Buy |
| 2020-02-12 | Iniziato | Citigroup | Buy |
| 2020-02-10 | Iniziato | Cowen | Outperform |
| 2019-04-08 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-24 | Iniziato | Jefferies | Buy |
| 2018-03-19 | Ripresa | Leerink Partners | Outperform |
| 2017-11-29 | Reiterato | Citigroup | Buy |
| 2017-11-22 | Reiterato | Ladenburg Thalmann | Buy |
| 2017-10-17 | Ripresa | Leerink Partners | Outperform |
| 2016-03-31 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-03-09 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-03 | Iniziato | Citigroup | Buy |
Mostra tutto
Ardelyx Inc Borsa (ARDX) Ultime notizie
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
Ardelyx (ARDX) director granted RSUs and 39,715-share stock option - Stock Titan
Laura A. Williams proposes sale of 31,000 shares (ARDX) - Stock Titan
Ardelyx (ARDX) director receives 26,455 RSUs and 39,715-share option - Stock Titan
Equity grants to Ardelyx (ARDX) director under compensation program - Stock Titan
Ardelyx (ARDX) director Cadoret-Manier receives RSU and option grants - Stock Titan
Ardelyx (ARDX) director receives RSUs and stock options as compensation - Stock Titan
Ardelyx (NASDAQ: ARDX) director awarded RSUs and stock options grant - Stock Titan
Ardelyx (ARDX) director Robert Bazemore receives RSU and option awards - Stock Titan
Ardelyx Inc (ARDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ardelyx Inc (ARDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ardelyx Inc (ARDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ardelyx Inc (ARDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ardelyx shareholders approve director elections and equity plan amendment By Investing.com - Investing.com Canada
Ardelyx shareholders approve director elections and equity plan amendment - Investing.com
Ardelyx Inc (ARDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ardelyx approves Equity Plan Amendment at 2026 Annual Meeting - TradingView
Ardelyx (NASDAQ: ARDX) shareholders approve equity plan, directors and auditor at 2026 meeting - Stock Titan
Ardelyx Inc (ARDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ardelyx (ARDX) CEO trades shares under 10b5-1 plan, exercises options - Stock Titan
ARDX insider Michael G. Raab sells 179,748 shares (NASDAQ: ARDX) - Stock Titan
Ardelyx (ARDX) Stock Could Be 65% Undervalued As Growth Hopes Face Reassessment - simplywall.st
Ardelyx Inc (ARDX) Institutional Confidence - TradingKey
ARDX Assumes Buy by Ladenburg Thalmann -- Price Target Announced at $16 - GuruFocus
Ardelyx Inc (ARDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
ARDX (NASDAQ) insider sales: 125,000 shares notice; Raab 10b5-1 trades listed - Stock Titan
ARDX edges up after hours on IBSRELA momentum and profitability 'right around the corner' - MSN
Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility - Yahoo Finance
Ardelyx eyes $500M+ revenue as IBSRELA growth puts profitability within reach - MSN
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Hyperphosphatemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharma - Barchart
ARDX Q1 2026 Earnings: Earnings Miss But Stock Gains as Investors Focus on Pipeline ProgressHigh Estimate Range - newsline.com
ARDX Q1 2026 Earnings: EPS Misses Estimates Slightly, Stock Gains Amid Mixed SignalsEarnings Revision Report - newsline.com
· SEC Filing - MLQ.ai
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Pullback And Growth Expectations - simplywall.st
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - TMX Newsfile
Ardelyx Advances Long-Term Tenapanor Trial in Chronic Constipation: What Investors Should Watch - TipRanks
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach - TradingView
Ardelyx Inc Azioni (ARDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):